Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Change in Management
Mankind Pharma appointed Nilesh Kulkarni as the new Head of Human Resource Functions for the Group, designated as Senior Management Personnel, effective June 8, 2026. This change is part of an internal organizational restructuring.
Jun 08 2026 22:22:06
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Mankind Pharma management will attend investor conferences in Mumbai on June 1 and June 2, 2026. Discussions will focus on the general business outlook, with no unpublished price sensitive information to be disclosed.
May 27 2026 16:14:36
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Mankind Pharma's management will hold meetings with various investors in Singapore on May 25 and 26, 2026. These discussions will focus on the general business outlook, with no unpublished price sensitive information being disclosed.
May 20 2026 21:16:08
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Mankind Pharma has made available the audio recording of its investor conference call for Q4 & FY26 results. The call, held on May 20, 2026, features discussions with senior management and provides insights into the company's performance.
May 20 2026 16:06:48
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Mankind Pharma's Q4 FY26 revenue increased by 11.8% YoY to INR 3,443 Cr. The company's adjusted EBITDA margin expanded by 400 bps to 27.1%, reflecting strong operational performance for the quarter.
May 19 2026 20:06:12
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Change in Management
Mankind Pharma's board approved the re-appointment of Mr. Satish Kumar Sharma as Whole-Time Director for another 5-year term. This re-appointment is effective from September 23, 2026, and is subject to shareholder approval at the upcoming AGM, ensuring continuity in leadership.
May 19 2026 19:31:16
Mankind Pharma Ltd - 543904 - Board Meeting Outcome for Please Find Attached The Audited Financial Results For The Quarter And Financial Year Ended March 31, 2026
Mankind Pharma's board approved Q4 FY26 cons. financial results, reporting revenue of ₹3,557.22 cr and net profit of ₹559.42 cr. The board also reappointed Satish Kumar Sharma as Whole-Time Director for five years and approved a ₹500 cr investment in its subsidiary, Mankind Medicare Private Limited.
May 19 2026 19:24:08
Read More